These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37343780)

  • 21. Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy.
    Huang X; Zhang W
    Small Methods; 2024 Aug; 8(8):e2301326. PubMed ID: 38040834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
    Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of immune checkpoint blockade in breast cancer.
    Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
    Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
    Wang X; Li X; Ito A; Sogo Y; Ohno T
    Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
    Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
    Tambunlertchai S; Geary SM; Naguib YW; Salem AK
    AAPS J; 2023 Jun; 25(4):57. PubMed ID: 37266761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
    van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
    Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
    Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
    Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical- and Chemical-Dually ROS-Responsive Nano-in-Gel Platforms with Sequential Release of OX40 Agonist and PD-1 Inhibitor for Augmented Combination Immunotherapy.
    Fu Y; Huang Y; Li P; Wang L; Tang Z; Liu X; Bian X; Wu S; Wang X; Zhu B; Yu Y; Jiang J; Li C
    Nano Lett; 2023 Feb; 23(4):1424-1434. PubMed ID: 36779813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report:
    Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
    Front Immunol; 2021; 12():752563. PubMed ID: 35003064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
    Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
    Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
    J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.